Access Pharmaceuticals Announces New MuGard Commercial Strategy in Nor...(rd to working with the Access team while...),Health

Date:7/29/2009

rd to working with the Access team while preparing for a MuGard launch in North America and bringing additional pharma resources to bear as needed. These efforts will not only maximize the potential for MuGard but, more importantly, provide access and availability for patients; thus improving outcomes I continue to believe that MuGard is a very important product for the cancer community, as the negative impact of oral mucositis on patient health and treatment is very significant."

MuGard is a novel, ready-to-use mucoadhesive oral wound rinse for the management of oral mucositis, a debilitating side effect of many anticancer treatments. Up to 80% of all patients receiving radiotherapy and approximately 40% of all chemotherapy patients develop oral mucositis, and almost all patients receiving radiotherapy for head and neck cancer and those undergoing stem cell transplantation develop mucositis. Updated clinical practice guidelines for the prevention and treatment of mucositis recommend the use of a preventive oral care regimen as part of routine supportive care along with a therapeutic oral care regimen if mucositis develops. The market for the treatment of oral mucositis, expanding to include all patients undergoing chemotherapy and radiotherapy, is estimated to be in excess of $5 billion world-wide.

MuGard forms a protective coating over the oral mucosa when swirled gently around the mouth. In a comparison of cancer patients receiving standard mucositis care with those patients receiving MuGard, the incidence and severity of mucositis was significantly lower in the MuGard treated group using a validated scale for the assessment of oral mucositis.

The previously announced licensing agreement between Access and Milestone Biosciences, LLC for North American rights to MuGard has been terminated.

About Access:<
'/>"/>

SOURCE Access Pharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine news :

1. The State of Louisiana and Together Rx Access Join Forces to Improve Prescription Access for Uninsured Residents
2. Fingertip Formulary Accounts(R) Now Offers Access to Comprehensive Real-Time Account Information and Integrated Formulary Data, in a State-of-the Art Web-Based Platform
3. Access Pharmaceuticals Announces Commercial Launch of MuGard(TM) in Norway by SpePharm
4. Cold Laser Technology Made Even More Accessible with Powerful New Product Available from Laser-Therapy.US
5. Accuray Announces CyberKnife Access Remote Service Product
6. President Obama Announces Intention to Sign United Nations Convention on the Rights of Persons with Disabilities, Impacts Accessible ICT
7. Cost-Conscious Texans Find Relief with Direct Access Lab Testing
8. UPDATE: Access Pharmaceuticals to Present at Jesup & Lamont 2009 Growth Stock Conference
9. Access Pharmaceuticals to Present at Jesup & Lamont 2009 Growth Stock Conference
10. Access Pharmaceuticals to Present at Jessup & Lamont 2009 Growth Stock Conference
11. Carefx Implements Fusionfx at Fletcher Allen Health Care to Improve Anywhere/Anytime Access to Crucial Patient Information